[3] Carrie C, Magne N, Burban-Provost P, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up...
[4]Prostate Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. [5]Brown J E, Handforth C, Compston J E, et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone ...
[2] Van den Broeck T, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2019 Jun;75(6):967-987. [3] Briganti A, et al. ...
[9]Mottet N, et al. EAU/ESTRO/ESUR/SIOG Guidelines on Prostate Cancer 2020. [10]Clegg NJ, Wongvipat J, Joseph JD, et al. Arn-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494-1503. [11]Chi K N, Agarwal N, Bjartell A, et al. Apalutamide...
[4]Prostate Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. [5]Brown J E, Handforth C, Compston J E, et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone...
原文出处:Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorizationapplication for Relugolix for the Treatment of Advanced Prostate Cancer 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人...
Intermittent ADT (androgen deprivation therapy) was proposed to prolong androgen dependency of prostate cancer and was found to possess potential benefits of reduced toxicities during the off-treatment period. For application of intermittent ADT, ADT with LHRH agonist or antagonist is introduced, and ...
surgical conditions for the patient to undergo surgical resection. KEYWORDS:Prostate cancer;Hormone sensitive;Enzalutamide;Treatment Corresponding author:Wang Zhiping, Email:nc.ude.uzlpzwyrE FUNDING: Special Fund for Basic Scientific Research Business Expenses of Central Universities of Lanzhou University(lzu...
[4]Prostate Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. [5]Brown J E, Handforth C, Compston J E, et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone...
Kishan AU, Steigler A, Denham JW, et al. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol. Published online Jan...